Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating

2026-03-10 14:08:54 ET

The last time I spoke about Dianthus Therapeutics, Inc. ( DNTH ), it was in a Seeking Alpha article entitled " Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition ." With respect to this article, I mentioned that the company was in the process of developing claseprubart [known as DNTH103 at that time] for the treatment of patients with Myasthenia Gravis [MG] in the ongoing phase 2 MaGic trial. I had a Buy rating at that time, and the stock has gained 174.53% since then....

Read the full article on Seeking Alpha

For further details see: